TABLE OF CONTENTS
1 INTRODUCTION 20
1.1 OBJECTIVES OF THE STUDY 20
1.2 MARKET DEFINITION 20
1.3 OVERVIEW OF NASAL SPRAY MARKET 21
1.4 CURRENCY AND PRICING 22
1.5 LIMITATION 22
1.6 MARKETS COVERED 22
2 MARKET SEGMENTATION 25
2.1 MARKETS COVERED 25
2.2 GEOGRAPHIC SCOPE 26
2.3 YEARS CONSIDERED FOR THE STUDY 27
2.4 CURRENCY AND PRICING 27
2.5 RESEARCH METHODOLOGY 28
2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 31
2.7 SECONDARY SOURCES 32
2.8 ASSUMPTIONS 32
3 MARKET OVERVIEW 33
3.1 DRIVERS 35
3.1.1 IMPROVING PATIENT COMPLIANCE AND ACCEPTABILITY 35
3.1.2 EFFECTIVENESS OVER OTHER FORMS OF DRUG DELIVERY 36
3.1.3 INCREASE IN INFECTION & ALLERGIC CASES 37
3.2 RESTRAINTS 37
3.2.1 PRODUCT RECALLS 37
3.3 OPPORTUNITIES 38
3.3.1 NEW RISING DEMAND FOR SELF ADMINISTRATIVE DRUG DELIVERY 38
3.3.2 EXPANDING THERAPEUTIC APPLICATIONS FOR NASAL SPRAYS 38
3.4 CHALLENGES 39
3.4.1 REGULATORY HURDLES 39
4 EXECUTIVE SUMMARY 40
5 PREMIUM INSIGHTS 44
?
6 NORTH AMERICA NASAL SPRAY MARKET, BY PRODUCT TYPE 46
6.1 OVERVIEW 47
6.2 DECONGESTION NASAL SPRAY 49
6.3 SALT WATER SOLUTION/ SALINE NASAL SPRAY 50
6.4 STEROID NASAL SPRAY 52
6.5 OTHERS 53
7 NORTH AMERICA N ASAL SPRAY MARKET, BY CONTAINER DESIGN 54
7.1 OVERVIEW 55
7.2 PRESSURIZED CANISTERS 57
7.3 PUMP BOTTLES 58
8 NORTH AMERICA NASAL SPRAY MARKET, BY DOSAGE FORM 59
8.1 OVERVIEW 60
8.2 UNIT/SINGLE DOSE 62
8.3 BI DOSE 64
8.4 MULTI DOSE 65
9 NORTH AMERICA NASAL SPRAY MARKET, BY THERAPEUTIC CLASS 67
9.1 OVERVIEW 68
9.2 ANTIHISTAMINE 70
9.3 NASAL STEROIDS 72
9.4 MAST CELL INHIBITOR 73
9.5 ANTICHOLINERGIC 74
10 NORTH AMERICA NASAL SPRAY MARKET, BY APPLICATION 75
10.1 OVERVIEW 76
10.2 ALLERGIC AND NON-ALLERGIC RHINITIS 78
10.3 NASAL CONGESTION 80
10.4 CENTRAL NERVOUS SYSTEM DISORDERS 81
10.5 VACCINATION 82
10.6 OTHERS 83
11 NORTH AMERICA NASAL SPRAY MARKET, BY PRESCRIPTION MODE 84
11.1 OVERVIEW 85
11.2 PRESCRIPTION BASED 87
11.3 OVER THE COUNTER 88
?
12 NORTH AMERICA NASAL SPRAY MARKET, BY END USER 90
12.1 OVERVIEW 91
12.2 HOSPITALS 93
12.3 CLINICS 94
12.4 HOME CARE SETTINGS 95
12.5 COMMUNITY HEALTH CARE 96
13 NORTH AMERICA NASAL SPRAY MARKET, BY GEOGRAPHY 97
13.1 NORTH AMERICA 97
13.1.1 INCREASING MANUFACTURING CAPABILITIES IN U.S. 97
13.1.2 U.S. 105
13.1.3 CANADA 109
13.1.4 MEXICO 113
14 NORTH AMERICA NASAL SPRAY MARKET, COMPANY LANDSCAPE 117
14.1 COMPANY SHARE ANALYSIS; NORTH AMERICA 117
15 COMPANY PROFILE 118
15.1 PFIZER INC. 118
15.1.1 COMPANY OVERVIEW 118
15.1.2 REVENUE ANALYSIS 118
15.1.3 COMPANY SHARE ANALYSIS 119
15.1.4 PRODUCT PORTFOLIO 120
15.1.5 RECENT DEVELOPMENTS 120
15.2 CIPLA INC. 121
15.2.1 COMPANY OVERVIEW 121
15.2.2 REVENUE ANALYSIS 121
15.2.3 COMPANY SHARE ANALYSIS 122
15.2.4 PRODUCT PORTFOLIO 122
15.2.5 RECENT DEVELOPMENTS 123
15.3 BAYER AG 124
15.3.1 COMPANY OVERVIEW 124
15.3.2 REVENUE ANALYSIS 124
15.3.3 COMPANY SHARE ANALYSIS 125
15.3.4 PRODUCT PORTFOLIO 125
15.3.5 RECENT DEVELOPMENTS 125
?
15.4 INNOVUS PHARMACEUTICALS, INC. 126
15.4.1 COMPANY OVERVIEW 126
15.4.2 REVENUE ANALYSIS 126
15.4.3 COMPANY SHARE ANALYSIS 127
15.4.4 PRODUCT PORTFOLIO 127
15.4.5 RECENT DEVELOPMENTS 127
15.5 GLAXOSMITHKLINE PLC. 128
15.5.1 COMPANY OVERVIEW 128
15.5.2 REVENUE ANALYSIS 128
15.5.3 PRODUCT PORTFOLIO 129
15.5.4 RECENT DEVELOPMENTS 129
15.6 ADAPT PHARMA, INC. 130
15.6.1 COMPANY OVERVIEW 130
15.6.2 GEOGRAPHIC PRESENCE 130
15.6.3 PRODUCT PORTFOLIO 131
15.6.4 RECENT DEVELOPMENTS 131
15.7 AISHWARYA GROUP 132
15.7.1 COMPANY OVERVIEW 132
15.7.2 PRODUCT PORTFOLIO 132
15.7.3 RECENT DEVELOPMENTS 132
15.8 ALLERGAN 133
15.8.1 COMPANY OVERVIEW 133
15.8.2 REVENUE ANALYSIS 133
15.8.3 PRODUCT PORTFOLIO 133
15.8.4 RECENT DEVELOPMENTS 134
15.9 ARIUS FORMULATIONS PVT LTD 135
15.9.1 COMPANY OVERVIEW 135
15.9.2 PRODUCT PORTFOLIO 135
15.9.3 RECENT DEVELOPMENTS 135
15.10 AURENA 136
15.10.1 COMPANY OVERVIEW 136
15.10.2 GEOGRAPHIC PRESENCE 136
15.10.3 PRODUCT PORTFOLIO 137
15.10.4 RECENT DEVELOPMENTS 137
15.11 CATALENT, INC 138
15.11.1 COMPANY OVERVIEW 138
15.11.2 REVENUE ANALYSIS 138
15.11.3 PRODUCT PORTFOLIO 139
15.11.4 RECENT DEVELOPMENTS 139
?
15.12 EGALET CORPORATION 140
15.12.1 COMPANY OVERVIEW 140
15.12.2 REVENUE ANALYSIS 140
15.12.3 PRODUCT PORTFOLIO 141
15.12.4 RECENT DEVELOPMENTS 141
15.13 J PHARMACEUTICALS 142
15.13.1 COMPANY OVERVIEW 142
15.13.2 PRODUCT PORTFOLIO 142
15.13.3 RECENT DEVELOPMENTS 142
15.14 LEEFORD HEALTHCARE LTD 143
15.14.1 COMPANY OVERVIEW 143
15.14.2 GEOGRAPHIC PRESENCE 143
15.14.3 PRODUCT PORTFOLIO 144
15.14.4 RECENT DEVELOPMENTS 144
15.15 MYLAN N.V. 145
15.15.1 REVENUE ANALYSIS 145
15.15.2 PRODUCT PORTFOLIO 146
15.15.3 RECENT DEVELOPMENTS 146
15.16 SANDOZ INTERNATIONAL GMBH 147
15.16.1 COMPANY OVERVIEW 147
15.16.2 GEOGRAPHIC PRESENCE 147
15.16.3 PRODUCT PORTFOLIO 148
15.16.4 RECENT DEVELOPMENTS 148
15.17 ST. RENATUS 149
15.17.1 COMPANY OVERVIEW 149
15.17.2 PRODUCT PORTFOLIO 149
15.17.3 RECENT DEVELOPMENTS 149
15.18 TEVA PHARMACEUTICAL INDUSTRIES LTD. 150
15.18.1 COMPANY OVERVIEW 150
15.18.2 REVENUE ANALYSIS 150
15.18.3 PRODUCT PORTFOLIO 151
15.18.4 RECENT DEVELOPMENTS 151
15.19 ULTRATECH INDIA LIMITED 152
15.19.1 COMPANY OVERVIEW 152
15.19.2 PRODUCT PORTFOLIO 152
15.19.3 RECENT DEVELOPMENTS 152
16 RELATED REPORTS 153